TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines

Brooke E. Hjelm, Jacquelyn Kilbourne, Melissa Herbst-Kralovetz

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Virus-like particles (VLPs) are an active area of vaccine research, development and commercialization. Mucosal administration of VLPs provides an attractive avenue for delivery of vaccines with the potential to produce robust immune responses. Nasal and oral delivery routes are particularly intriguing due to differential activation of mucosa-associated lymphoid tissues. We compared both intranasal and oral administration of VLPs with a panel of toll-like receptor (TLR) agonists (TLR3, 5, 7, 7/8, and 9) to determine the mucosal adjuvant activity of these immunomodulators. We selected Norwalk virus (NV) VLPs because it is an effective model antigen and an active area of research and commercialization.To prioritize these adjuvants, VLP-specific antibody production in serum (IgG, IgG1, IgG2a), vaginal lavages (IgG, IgA), and fecal pellets (IgA) were measured across a longitudinal timeseries in vaccinated mice. Additional distal mucosal sites (nasal, brochoalveolar, salivary, and gastrointestinal) were evaluated for VLP-specific responses (IgA). Intranasal co-delivery of VLPs with TLR7 or TLR9 agonists produced the most robust and broad-spectrum immune responses, systemically and at distal mucosal sites inducing VLP-specific antibodies at all sites evaluated. In addition, these VLPspecific antibodies blocked binding of NV VLPs to histo-blood group antigen (H type 1), supporting their functionality. Oral administration and/or other TLR agonists tested in the panel did not consistently enhance VLP-specific immune responses. This study demonstrates that intranasal co-delivery of VLPs with TLR7 or TLR9 agonists provides dose-sparing advantages for induction of specific and functional antibody responses against VLPs (i.e., non-replicating antigens) in the respiratory, gastrointestinal, and reproductive tract.

Original languageEnglish (US)
Pages (from-to)410-416
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Virus-Like Particle Vaccines
Norovirus
Virion
Norwalk virus
Technology Transfer
Toll-Like Receptors
Nose
Immunoglobulin A
Antibody Formation
Oral Administration
Mucosal Administration
Vaginal Douching
Vaccines
ABO Blood-Group System
Antigens
Intranasal Administration
Antibodies
Immunologic Factors
Lymphoid Tissue

Keywords

  • Antibody production
  • Mucosal adjuvants
  • Mucosal immunology
  • Nasal vaccination
  • Norovirus
  • Oral vaccination
  • TLR agonists
  • Virus-like particles

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Medicine(all)

Cite this

TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. / Hjelm, Brooke E.; Kilbourne, Jacquelyn; Herbst-Kralovetz, Melissa.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 2, 2014, p. 410-416.

Research output: Contribution to journalArticle

@article{96428f7245af4939aa248a8be40e1fe9,
title = "TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines",
abstract = "Virus-like particles (VLPs) are an active area of vaccine research, development and commercialization. Mucosal administration of VLPs provides an attractive avenue for delivery of vaccines with the potential to produce robust immune responses. Nasal and oral delivery routes are particularly intriguing due to differential activation of mucosa-associated lymphoid tissues. We compared both intranasal and oral administration of VLPs with a panel of toll-like receptor (TLR) agonists (TLR3, 5, 7, 7/8, and 9) to determine the mucosal adjuvant activity of these immunomodulators. We selected Norwalk virus (NV) VLPs because it is an effective model antigen and an active area of research and commercialization.To prioritize these adjuvants, VLP-specific antibody production in serum (IgG, IgG1, IgG2a), vaginal lavages (IgG, IgA), and fecal pellets (IgA) were measured across a longitudinal timeseries in vaccinated mice. Additional distal mucosal sites (nasal, brochoalveolar, salivary, and gastrointestinal) were evaluated for VLP-specific responses (IgA). Intranasal co-delivery of VLPs with TLR7 or TLR9 agonists produced the most robust and broad-spectrum immune responses, systemically and at distal mucosal sites inducing VLP-specific antibodies at all sites evaluated. In addition, these VLPspecific antibodies blocked binding of NV VLPs to histo-blood group antigen (H type 1), supporting their functionality. Oral administration and/or other TLR agonists tested in the panel did not consistently enhance VLP-specific immune responses. This study demonstrates that intranasal co-delivery of VLPs with TLR7 or TLR9 agonists provides dose-sparing advantages for induction of specific and functional antibody responses against VLPs (i.e., non-replicating antigens) in the respiratory, gastrointestinal, and reproductive tract.",
keywords = "Antibody production, Mucosal adjuvants, Mucosal immunology, Nasal vaccination, Norovirus, Oral vaccination, TLR agonists, Virus-like particles",
author = "Hjelm, {Brooke E.} and Jacquelyn Kilbourne and Melissa Herbst-Kralovetz",
year = "2014",
doi = "10.4161/hv.27147",
language = "English (US)",
volume = "10",
pages = "410--416",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines

AU - Hjelm, Brooke E.

AU - Kilbourne, Jacquelyn

AU - Herbst-Kralovetz, Melissa

PY - 2014

Y1 - 2014

N2 - Virus-like particles (VLPs) are an active area of vaccine research, development and commercialization. Mucosal administration of VLPs provides an attractive avenue for delivery of vaccines with the potential to produce robust immune responses. Nasal and oral delivery routes are particularly intriguing due to differential activation of mucosa-associated lymphoid tissues. We compared both intranasal and oral administration of VLPs with a panel of toll-like receptor (TLR) agonists (TLR3, 5, 7, 7/8, and 9) to determine the mucosal adjuvant activity of these immunomodulators. We selected Norwalk virus (NV) VLPs because it is an effective model antigen and an active area of research and commercialization.To prioritize these adjuvants, VLP-specific antibody production in serum (IgG, IgG1, IgG2a), vaginal lavages (IgG, IgA), and fecal pellets (IgA) were measured across a longitudinal timeseries in vaccinated mice. Additional distal mucosal sites (nasal, brochoalveolar, salivary, and gastrointestinal) were evaluated for VLP-specific responses (IgA). Intranasal co-delivery of VLPs with TLR7 or TLR9 agonists produced the most robust and broad-spectrum immune responses, systemically and at distal mucosal sites inducing VLP-specific antibodies at all sites evaluated. In addition, these VLPspecific antibodies blocked binding of NV VLPs to histo-blood group antigen (H type 1), supporting their functionality. Oral administration and/or other TLR agonists tested in the panel did not consistently enhance VLP-specific immune responses. This study demonstrates that intranasal co-delivery of VLPs with TLR7 or TLR9 agonists provides dose-sparing advantages for induction of specific and functional antibody responses against VLPs (i.e., non-replicating antigens) in the respiratory, gastrointestinal, and reproductive tract.

AB - Virus-like particles (VLPs) are an active area of vaccine research, development and commercialization. Mucosal administration of VLPs provides an attractive avenue for delivery of vaccines with the potential to produce robust immune responses. Nasal and oral delivery routes are particularly intriguing due to differential activation of mucosa-associated lymphoid tissues. We compared both intranasal and oral administration of VLPs with a panel of toll-like receptor (TLR) agonists (TLR3, 5, 7, 7/8, and 9) to determine the mucosal adjuvant activity of these immunomodulators. We selected Norwalk virus (NV) VLPs because it is an effective model antigen and an active area of research and commercialization.To prioritize these adjuvants, VLP-specific antibody production in serum (IgG, IgG1, IgG2a), vaginal lavages (IgG, IgA), and fecal pellets (IgA) were measured across a longitudinal timeseries in vaccinated mice. Additional distal mucosal sites (nasal, brochoalveolar, salivary, and gastrointestinal) were evaluated for VLP-specific responses (IgA). Intranasal co-delivery of VLPs with TLR7 or TLR9 agonists produced the most robust and broad-spectrum immune responses, systemically and at distal mucosal sites inducing VLP-specific antibodies at all sites evaluated. In addition, these VLPspecific antibodies blocked binding of NV VLPs to histo-blood group antigen (H type 1), supporting their functionality. Oral administration and/or other TLR agonists tested in the panel did not consistently enhance VLP-specific immune responses. This study demonstrates that intranasal co-delivery of VLPs with TLR7 or TLR9 agonists provides dose-sparing advantages for induction of specific and functional antibody responses against VLPs (i.e., non-replicating antigens) in the respiratory, gastrointestinal, and reproductive tract.

KW - Antibody production

KW - Mucosal adjuvants

KW - Mucosal immunology

KW - Nasal vaccination

KW - Norovirus

KW - Oral vaccination

KW - TLR agonists

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=84896903153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896903153&partnerID=8YFLogxK

U2 - 10.4161/hv.27147

DO - 10.4161/hv.27147

M3 - Article

VL - 10

SP - 410

EP - 416

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 2

ER -